Simultaneously Decoding the Transcriptome, Epigenome and 3D Genome Within a Single Cell

Why It Matters

By delivering a unified, cost‑effective view of gene activity, epigenetic regulation, and spatial genome organization, scHiCAR accelerates discovery of early disease mechanisms and supports development of targeted therapies. Its scalability makes large‑scale, single‑cell multi‑omics feasible for both research and clinical pipelines.

Key Takeaways

• scHiCAR maps transcriptome, epigenome, 3D genome together.
• Costs drop to $0.04 per cell, enabling large-scale studies.
• 1.6 million mouse brain cells profiled, revealing 22 cell types.
• AI integration boosts accuracy and reproducibility of multi-omics data.
• Real-time 3D genome dynamics observed during muscle regeneration.

Pulse Analysis

The rise of single‑cell multi‑omics has transformed how researchers dissect cellular heterogeneity, yet most platforms require separate assays for transcriptome, epigenome, and chromatin conformation. This fragmented approach forces costly data integration and often masks subtle regulatory events that drive disease onset. As a result, early‑stage biomarkers and mechanistic insights remain elusive, especially in complex tissues like the brain where cell types intermingle.

scHiCAR addresses these gaps by coupling high‑throughput RNA sequencing, ATAC‑based chromatin accessibility, and Hi‑C‑derived 3D genome mapping within the same nucleus. Leveraging machine‑learning pipelines, the system corrects technical noise and aligns the three data layers with unprecedented precision. At an estimated $0.04 per cell, the platform scales to millions of cells, exemplified by a 1.6 million‑cell mouse brain atlas that resolved 22 distinct cell populations and their spatial genome configurations. The cost reduction and AI‑driven analytics lower barriers for labs to adopt comprehensive single‑cell profiling without sacrificing depth.

The implications for biomedical research are profound. By pinpointing when and where disease‑associated genes become active, and how their three‑dimensional context reshapes during processes such as muscle regeneration, scHiCAR equips scientists to trace pathogenic trajectories from the earliest molecular cues. This granular insight fuels more accurate disease models, accelerates target validation, and paves the way for patient‑specific therapeutic design in fields ranging from neurodegeneration to oncology. As the technology matures, its integration into clinical pipelines could enable real‑time monitoring of treatment response at the single‑cell level.